The further parameters included decreased ALAT levels and lung function parameters (VC and DLCO), increased thrombocyte counts, INR, fibrinogen, GGT, CRP, CYFRA 21-1 levels, as well as Rhesus negativity, neoadjuvant chemotherapy, multilobar resections and tumor size > 3 cm (T2). This evidence concerns the gene CRP and neoplasm.